Whats new in jpnd
•Download as PPT, PDF•
1 like•1,361 views
MArta Gomex, JPND Management Board member delivered a JPND presentation at the JPIs-to-co-work final conference in Madrid on February 19th, 2014
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Whats new in jpnd
Similar to Whats new in jpnd (20)
More from jpndresearch
More from jpndresearch (7)
Recently uploaded
Recently uploaded (20)
Whats new in jpnd
- 1. What’s new in JPND? Marta Gomez JPND Management Board Member 19/02/2014
- 2. Joint Programming - a definition European countries engaging •voluntarily and on a variable geometry basis to tackle a major societal question •in the definition, development and implementation of a common strategic research agenda •based on a common vision on how to address major societal challenges.
- 3. We cannot tackle neurodegenerative diseases by acting as single countries Albania Austria Belgium Canada Croatia Czech Republic Denmark Finland France Germany Greece Hungary Ireland Israel Italy Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland Turkey United Kingdom JPND is a global research initiative led by EU countries, with 28 participating EU member states Associated countries Third countries Increasing coordination of national research programmes to improve impact and effectiveness
- 4. JPND brings together…. • Researchers (Basic, Clinical, Healthcare/Social) • National Funding Bodies • National Research Strategies and Investments
- 5. Current JPND strategy To increase coordinated investment in ND research aimed at finding causes of disease, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases • Immediate JPND goals: • To add value to national investments through coordinated action • To encourage the development of national research strategies in ND • To engage in partnership to reach the full potential of JPND
- 6. JPND currently partly supported by FP7-JUMPAHEAD (GA. 260774) Management Board • 27 countries represented • Members mandated to act • Chair Philippe Amouyel - France Executive Board • Vice-Chair Adriana Maggi - Italy • Robin Buckle - UK • Mogens Horder - Denmark • Marlies Dorlochter - Germany Scientific Advisory Board • 18 Members, chosen for scientific excellence and competence Organisation Steering Committee Executive Board + •Enda Connolly - Ireland •Rainer Girgenrath - Germany •Edvard Beem - Netherlands
- 7. DEFRAGMENTATION - WHAT JPND IS ALL ABOUT STRATEGIC RESEARCH AGENDA ALIGNMENT OF EU COUNTRIES ON COMMON RESEARCH GOALS
- 8. Scientific • Animal models • Biobanks • Cohorts/registries • Disease pathology Social • Health care delivery • Home automation • Health economics • Ethics Medical • Early diagnosis • Prevention • Clinical trialsFocus on Three Domains Scope of the initiative
- 9. JPND Research Strategy (SRA) • Agreed by 25 Member States + Assoc. Countries • Officially Launched Feb 7th 2012 • Thematic priorities for future research: • The origins of neurodegenerative disease • Disease mechanisms and models • Disease definitions and diagnosis • Developing therapies, preventive strategies and interventions • Healthcare and social care
- 10. How can JPND reach its goals? •Alignment of research in Member Countries •Partnership with the European Commission •Partnership with Industry •Partnership with other international organisations •Involvement of Patients and Public
- 11. JPND Actions to date • Common European Strategy • Phase I SRA Implementation (2012-2014) • Annual Transnational Calls for Proposals • Action Groups • National Plans and Strategies • Communication + Dissemination
- 12. SRA Implementation (2012-2014) Annual Calls for Proposals Centres of Excellence in Neurodegeneration (CoEN) •First call (2011) for € 6M – 8 projects •Second call (2012-13) for € 8M – 5 “Pathfinder” projects Year Total fund available Research Area No. of Projects 2011 (pilot) €16M Optimization of biomarkers + harmonization of their use 4 2012 €18M Risk and Protective Factors 5 2012 €11M Evaluation of Healthcare 6 2013 €12M Cross-Disease Analysis open call 2013 €11M Preventive Strategies open call
- 13. Call Statistics Biomarker call 2011 Risk factor call 2012 Healthcare 2012 Nb of proposals submitted / nb of partners / budget requested 14 / 165 / 30.8 M€ 52 / 307 / 97 M€ 22 / 122 / 29 M€ Nb of proposals accepted / nb of partners / budget allocated 4 / 88 / 13.6 M€ 5 / 41 / 17 M€ 6 / 41 / 9 M€ Success rate 29% 10% 27% Gender breakdown (partners) 23% 28% 42% Total no. of proposals submitted = 88 Total no. of partners involved = 594 Overall success rate = 17%
- 14. SRA Implementation (2012-2014) Action Groups • To determine transnational research needs and opportunities • Palliative Care (chair: E. Connolly) • Animal and Cell Models (chair: A. Maggi) • Assisted Living Technologies (chair J. Hoogendam) • Longitudinal Cohort Studies (chair: R. Buckle) • To promote engagement, commitment and partnerships • Engagement and partnership with the EC (chair: P. Amouyel) • Engagement and Partnership with Industry (chair: A. Maggi) • User and Public Involvement in ND Research (chair: M. Horder) • Linkage + Alignment of National Plans and Initiatives (chair: E. Hirsch)
- 16. JPND-supported projects Fact Sheets Publications
- 17. Monitoring & Evaluation • JPND monitoring and evaluation framework • Questionnaire on ‘attitudes towards JPND’ • External review of strategic direction + implementation
- 19. Online Partnering Tool Create Personal Profile Register Research Group
- 20. Online Partnering Tool Register a proposal idea and form consortia online
- 21. Partnering Tool Pilot Phase 480 User Profiles 550 User Profiles (30 Countries) 550 User Profiles (30 Countries)
- 22. Developing and Aligning ND research strategies •Most JPND countries • No national roadmap • No identified priority actions in the field of ND research •Those who do, take different approaches • Specific research programmes • National plans targeted to an individual disease (e.g. Dementia) • National plans comprising research, service delivery, both •Since deciding to participate in JPND, an increasing number of countries are working towards developing SRAs •Specific JPND actions aimed at encouraging countries to develop national research strategies in ND
- 23. Emerging national JPND-related activities • The Netherlands • Research a major theme as part of National Deltaplan for Dementia “…. the Deltaplan will follow closely the JPND strategic research agenda and will strengthen the international position of the Netherlands for both research and industry” Edith Schippers, Minister for Health, Welfare and Sport • United Kingdom • David Cameron’s “Prime Minister’s challenge on dementia” includes specific references to continued support for COEN and JPND research • Ireland • National SRA developed to inform participation in JPND • Researchers using participation in 2011 JPND Biomarkers call to start a national network in biomarkers for Alzheimer’s and Parkinson’s
- 24. Partnership with the European Commission • First call of Horizon 2020 (Dec. 2013) • ERA-NET: • “Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020”. • Proposal should: • coordinate national and regional programmes for research in the area of ND diseases research by implementing a transnational call with EU co-funding • promote the strategic alignment of research activities • demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness • plan the development of key indicators for supporting this. • implement other joint activities including training and additional joint calls without EU co-funding.
- 25. Declaration from G8 summit on dementia • In response, the OECD is launching a project in 2014 for research on Alzheimer’s and dementia: • Aimed at strengthening international collaboration and promote data sharing at the international level. • JPND invited to join the project Advisory Group • OECD plans a G8 mapping based upon JPND mapping methodology
- 26. Keep up to date • Visit the JPND website: • http://www.neurodegenerationresearch.eu • http://www.jpnd.eu • Sign up to the JPND News Feeds • Follow JPND Progress pages • E-mail us: secretariat@jpnd.eu • Follow us on Twitter: @JPNDEurope
Editor's Notes
- The challenge of addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s is a truly global one. Most neurodegenerative diseases (ND) are incurable and are strongly linked with age. Dementias alone affect more than 7 million people in Europe and their care is estimated to cost €130 billion a year. This heavy burden on the individuals with disease, their relatives, and society as a whole is a problem that will only get worse as the European population inexorably ages, and the number of people working in care continues to decrease. Close to 85% of public research funds in the EU are spent independently by Member States
- This will be achieved by coordinating current and future approaches collaborating where appropriate sharing tools, techniques and other resources more efficiently among participating countries
- Over €100 million will be made available
- Reports and recommendations from Action Groups feed into the overall Phase 1 Implementation plan, with the JPND Management Board making the decision on which initiatives to start and when to start them. You can keep up-to-date on outputs from Action Groups, and funded projects on the “JPND Progress” pages on the JPND website
- You can also view the JPND-supported projects though the Fact Sheets provided on our website. Many of the ongoing projects are starting to produce their scientific and research outputs (incl. publications, guidelines, etc.)
- Indeed, JPND has its own monitoring framework in which it captures the impact that JPND is making on the field of ND research, as well as how the concept of joint programming is progressing (JPND is, after all, the pilot JPI). Bastain Mostert of Technopolis will be talking in greater detail on this side of things later today.
- JPND is implementing a series of actions designed to engage its important stakeholder groups. These actions must service the needs and objectives of JPND and provide concrete benefits for its broad stakeholder community. A notable outcome of engagements to date has been the potential role for JPND to act as a medium to encourage deeper levels of collaboration between research communities from diverse backgrounds (e.g. biomedical researchers, healthcare researchers, patient organisations, industry). An opportunity arose in collaboration with the Norwegian networking group – NNN, and the INDUCT software company, that could encourage greater levels of collaboration between groups planning to submit proposals to JPND calls. A pilot partnering tool has been designed to do this and was made available for the currently open calls.
- The full potential of JPND will only be reached if participating countries without research strategies in ND can be encouraged to identify their strengths and weaknesses, and agree that supporting neurodegenerative disease research is a national priority
- Recent national plans include references to JPND Dutch Deltaplan for Dementia, UK Prime Minister’s Challenge on Dementia
- The OECD is establishing an Expert Group to provide advice and guidance to this project. The JPND is invited to join this advisory Group and provide additional information on its terms of reference. OECD plans a G8 mapping based upon JPND mapping methodology. The project will involve a stocktaking exercise on the most important issues regarding international access and sharing of data resources for Alzheimer’s and dementia.